Clinical grade purification and expansion of natural killer cells

Critical Reviews in Oncogenesis

Volumn 19, Issue 1-2, 2014, Pages 121-132

  Lapteva, Natalia ^a   Szmania, Susann M ^b   Van Rhee, Frits ^b   Rooney, Cliona M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Adoptive transfer; Clinical products; Manufacture; Natural killer cells

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL EXPANSION; EX VIVO STUDY; HUMAN; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

HUMANS; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84899649655     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2014010931     Document Type: Article

References (25)

1. Boyiadzis M, Foon KA, Herberman RB. NK cells in cancer immunotherapy: three decades of discovery. Discov Med. 2006 Dec;6(36):243-248.
2. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005 Apr 15;105(8):3051-3057.
3. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010 Nov;59(11):1739-1744.
4. Basse PH, Whiteside TL, Chambers W, Herberman RB. Terapeutic activity of NK cells against tumors. Int Rev Immunol 2001 Jun;20(3-4):439-501.
5. Szmania S, Garg TK, Lapteva N, Lingo JD, Greenway AD, Stone K, Woods E, Khan J, Stivers J, Nair B, Baxter-Lowe LA, Bost A, Campana D, Epstein J, Gee AP, Brenner MK, Usmani SZ, Waheed S, Rooney CM, Cottler-Fox M, Barlogie B, van Rhee F. Fresh ex vivo expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma (MM) patients. Blood (ASH Annual Meeting Abstract) 120. 2012.
6. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J, Miller JS. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007 Mar;47(3):520-528.
7. Smith A, Khuu H, Betters DM, Cook L, Grasmeder S, Lopez R, Su S, Fellowes V, Stroncek D, Pantin J, Vasu S, Donohue T, Keyvanfar K, Childs R. Adoptive transfer of escalating doses of ex vivo expanded autolo-gous natural killer (NK) cells in patients with advanced malignancies following bortezo-mib treatment to sensitiza to NK-TRAIL Cytotoxicity. Blood (ASH Annual Meeting Abstract) 116[Abstract 4296]. 2010.
8. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct;14(9): 1131-1143.
9. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, Schaap N, Dolstra H. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011;6(6):e20740.
10. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013 Apr;2(4):274-283.
11. Pfeiffer MM, Schumm M, Muller I, Handgretinger R, Lang P. IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT. Leukemia. 2012 Nov;26(11):2435-2439.
12. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, MalaviarachchBarlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008 Dec;143(5):641-653.
13. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T, Favre G, Gratwohl A. Purifed donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004 Nov;18(11):1835-1838.
14. Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T, Sorensen J, Gruttner H P, Bader P, Seifried E, Martin H, Lang P, Passweg JR, Klingebiel T, Schwabe D. Ex vivo expansion of highly purifed NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 2005 Nov-Dec;217(6):345-350.
15. Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kwealramani T, Yu N, Van Etten RA, McKenna DH. Autologous stem cell transplant recipients tolerate haploidenti-cal related-donor natural killer cell-enriched infusions. Transfusion. 2013 Feb;53(2):412-418.
16. Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy. 2004;6(1):15-22.
17. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, Christensson B, Dilber MS. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol. 2001 Oct;62(10):1092-1098.
18. Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2004 Nov-Dec;33(3):261-266.
19. Berg M, Lundqvist A, McCoy P, Jr., Samsel L, Fan Y, Tawab A, Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341-355.
20. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009 May 1;69(9):4010-4017.
21. Imai C, Iwamoto S, Campana D. Genetic modifcation of primary natural killer cells overcomes inhibitory signals and induces spe-cifc killing of leukemic cells. Blood. 2005 Jul 1;106(1):376-383.
22. Boyle W, Chow A. Isolation of human lymphocytes by a Ficoll barrier method. Transfusion. 1969 May;9(3):151-155.
23. Lapteva N, Vera JF. Optimization manufacture of virus- and tumor-specifc T cells. Stem Cells Int. 2011;2011:434392.
24. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994 Apr;8(4):652-658.
25. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013 Dec;15(12):1563-1570.